Dyne Therapeutics has appointed Barry Greene to its Board of Directors. Greene brings more than 30 years of biopharmaceutical experience, with expertise in rare diseases, neuroscience, and oncology. He currently serves as lead independent director at Karyopharm Therapeutics and previously was CEO of Sage Therapeutics from December 2020 to July 2025. Before that, he spent 20 years at Alnylam Pharmaceuticals, most recently as President and COO. Dyne shares closed Monday at $20.87, up 5.40%.
Dyne Therapeutics IncAppointment of experienced biopharma executive Barry Greene to board is a positive governance signal.
Alnylam Pharmaceuticals Inc
Karyopharm Therapeutics Inc